Aristo Bio-Tech and Lifescience Limited

NSEI:ARISTO Stock Report

Market Cap: ₹645.4m

Aristo Bio-Tech and Lifescience Management

Management criteria checks 4/4

Aristo Bio-Tech and Lifescience's CEO is Narendra Barhat, appointed in Sep 2018, has a tenure of 7.75 years. directly owns 39.05% of the company’s shares, worth ₹252.00M. The average tenure of the management team and the board of directors is 7.8 years and 7.8 years respectively.

Key information

Narendra Barhat

Chief executive officer

₹3.6m

Total compensation

CEO salary percentagen/a
CEO tenure7.8yrs
CEO ownership39.0%
Management average tenure7.8yrs
Board average tenure7.8yrs

Recent management updates

Recent updates

Analysis Article Jun 09

Here's Why We Think Aristo Bio-Tech and Lifescience (NSE:ARISTO) Might Deserve Your Attention Today

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...
Analysis Article Sep 18

Aristo Bio-Tech and Lifescience Limited (NSE:ARISTO) Soars 26% But It's A Story Of Risk Vs Reward

Aristo Bio-Tech and Lifescience Limited ( NSE:ARISTO ) shares have had a really impressive month, gaining 26% after a...
Analysis Article Jul 03

Take Care Before Diving Into The Deep End On Aristo Bio-Tech and Lifescience Limited (NSE:ARISTO)

With a price-to-earnings (or "P/E") ratio of 21.8x Aristo Bio-Tech and Lifescience Limited ( NSE:ARISTO ) may be...
Analysis Article May 31

Estimating The Intrinsic Value Of Aristo Bio-Tech and Lifescience Limited (NSE:ARISTO)

Key Insights Aristo Bio-Tech and Lifescience's estimated fair value is ₹172 based on 2 Stage Free Cash Flow to Equity...
Analysis Article Mar 27

Do Aristo Bio-Tech and Lifescience's (NSE:ARISTO) Earnings Warrant Your Attention?

Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...
Analysis Article Feb 12

Is Aristo Bio-Tech and Lifescience (NSE:ARISTO) A Risky Investment?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Analysis Article Oct 30

Aristo Bio-Tech and Lifescience Limited (NSE:ARISTO) Doing What It Can To Lift Shares

When close to half the companies in India have price-to-earnings ratios (or "P/E's") above 32x, you may consider Aristo...
Analysis Article Aug 22

Is Aristo Bio-Tech and Lifescience (NSE:ARISTO) Using Too Much Debt?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...
Analysis Article Jun 29

Potential Upside For Aristo Bio-Tech and Lifescience Limited (NSE:ARISTO) Not Without Risk

When close to half the companies in India have price-to-earnings ratios (or "P/E's") above 33x, you may consider Aristo...
Analysis Article Mar 22

If EPS Growth Is Important To You, Aristo Bio-Tech and Lifescience (NSE:ARISTO) Presents An Opportunity

It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...

CEO Compensation Analysis

How has Narendra Barhat's remuneration changed compared to Aristo Bio-Tech and Lifescience's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

₹72m

Dec 31 2025n/an/a

₹54m

Sep 30 2025n/an/a

₹37m

Jun 30 2025n/an/a

₹39m

Mar 31 2025₹4mn/a

₹41m

Dec 31 2024n/an/a

₹50m

Sep 30 2024n/an/a

₹59m

Jun 30 2024n/an/a

₹49m

Mar 31 2024₹5mn/a

₹39m

Dec 31 2023n/an/a

₹37m

Sep 30 2023n/an/a

₹36m

Jun 30 2023n/an/a

₹36m

Mar 31 2023₹5mn/a

₹36m

Mar 31 2022₹5mn/a

₹14m

Mar 31 2021₹5mn/a

₹11m

Mar 31 2020₹5m₹5m

₹10m

Compensation vs Market: Narendra's total compensation ($USD37.94K) is about average for companies of similar size in the Indian market ($USD41.83K).

Compensation vs Earnings: Narendra's compensation has been consistent with company performance over the past year.


CEO

Narendra Barhat (71 yo)

7.8yrs
Tenure
₹3,609,900
Compensation

Mr. Narendra Singh Barhat serves as the Chairman & MD of Aristo Bio-Tech and Lifescience Limited since September 10, 2018. He served as a Director of Aristo Bio-Tech and Lifescience Limited since March 17,...


Leadership Team

NamePositionTenureCompensationOwnership
Narendra Barhat
Chairman & MD7.8yrs₹3.61m39.05%
₹ 252.0m
Ketankumar Joshi
Whole-Time Director & CFO7.8yrs₹2.20m10.58%
₹ 68.3m
Kusum Narendra Barhat
Executive Directorno data₹2.21m9.18%
₹ 59.3m
Diksha Peswani
Company Secretary & Compliance Officer1.1yrsno datano data
Anand Sharma
Vice President of Marketing & Salesno datano datano data
7.8yrs
Average Tenure
64yo
Average Age

Experienced Management: ARISTO's management team is seasoned and experienced (7.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Narendra Barhat
Chairman & MD21.3yrs₹3.61m39.05%
₹ 252.0m
Ketankumar Joshi
Whole-Time Director & CFO7.8yrs₹2.20m10.58%
₹ 68.3m
Kusum Narendra Barhat
Executive Director21.3yrs₹2.21m9.18%
₹ 59.3m
Raghavender Mateti
Non- Executive Independent Director7.8yrs₹108.00kno data
Rashmi Otavani
Non- Executive Independent Director4.3yrs₹112.00kno data
Laxman Rathore
Additional Non-Executive Director4.3yrsno datano data
7.8yrs
Average Tenure
67.5yo
Average Age

Experienced Board: ARISTO's board of directors are considered experienced (7.8 years average tenure).


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/12 15:41
End of Day Share Price 2026/06/12 00:00
Earnings2026/03/31
Annual Earnings2026/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Aristo Bio-Tech and Lifescience Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.